Bifunctional Anti-Non-Amyloid Component α-Synuclein Nanobodies Are Protective In Situ.

Misfolding, abnormal accumulation, and secretion of α-Synuclein (α-Syn) are closely associated with synucleinopathies, including Parkinson's disease (PD). VH14 is a human single domain intrabody selected against the non-amyloid component (NAC) hydrophobic interaction region of α-Syn, which is c...

Full description

Saved in:
Bibliographic Details
Main Authors: David C Butler, Shubhada N Joshi, Erwin De Genst, Ankit S Baghel, Christopher M Dobson, Anne Messer
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2016-01-01
Series:PLoS ONE
Online Access:https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0165964&type=printable
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849472620656852992
author David C Butler
Shubhada N Joshi
Erwin De Genst
Ankit S Baghel
Christopher M Dobson
Anne Messer
author_facet David C Butler
Shubhada N Joshi
Erwin De Genst
Ankit S Baghel
Christopher M Dobson
Anne Messer
author_sort David C Butler
collection DOAJ
description Misfolding, abnormal accumulation, and secretion of α-Synuclein (α-Syn) are closely associated with synucleinopathies, including Parkinson's disease (PD). VH14 is a human single domain intrabody selected against the non-amyloid component (NAC) hydrophobic interaction region of α-Syn, which is critical for initial aggregation. Using neuronal cell lines, we show that as a bifunctional nanobody fused to a proteasome targeting signal, VH14PEST can counteract heterologous proteostatic effects of mutant α-Syn on mutant huntingtin Exon1 and protect against α-Syn toxicity using propidium iodide or Annexin V readouts. We compared this anti-NAC candidate to NbSyn87, which binds to the C-terminus of α-Syn. NbSyn87PEST degrades α-Syn as well or better than VH14PEST. However, while both candidates reduced toxicity, VH14PEST appears more effective in both proteostatic stress and toxicity assays. These results show that the approach of reducing intracellular monomeric targets with novel antibody engineering technology should allow in vivo modulation of proteostatic pathologies.
format Article
id doaj-art-fda9170016e14126bcbaf644edb3fdcf
institution Kabale University
issn 1932-6203
language English
publishDate 2016-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj-art-fda9170016e14126bcbaf644edb3fdcf2025-08-20T03:24:29ZengPublic Library of Science (PLoS)PLoS ONE1932-62032016-01-011111e016596410.1371/journal.pone.0165964Bifunctional Anti-Non-Amyloid Component α-Synuclein Nanobodies Are Protective In Situ.David C ButlerShubhada N JoshiErwin De GenstAnkit S BaghelChristopher M DobsonAnne MesserMisfolding, abnormal accumulation, and secretion of α-Synuclein (α-Syn) are closely associated with synucleinopathies, including Parkinson's disease (PD). VH14 is a human single domain intrabody selected against the non-amyloid component (NAC) hydrophobic interaction region of α-Syn, which is critical for initial aggregation. Using neuronal cell lines, we show that as a bifunctional nanobody fused to a proteasome targeting signal, VH14PEST can counteract heterologous proteostatic effects of mutant α-Syn on mutant huntingtin Exon1 and protect against α-Syn toxicity using propidium iodide or Annexin V readouts. We compared this anti-NAC candidate to NbSyn87, which binds to the C-terminus of α-Syn. NbSyn87PEST degrades α-Syn as well or better than VH14PEST. However, while both candidates reduced toxicity, VH14PEST appears more effective in both proteostatic stress and toxicity assays. These results show that the approach of reducing intracellular monomeric targets with novel antibody engineering technology should allow in vivo modulation of proteostatic pathologies.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0165964&type=printable
spellingShingle David C Butler
Shubhada N Joshi
Erwin De Genst
Ankit S Baghel
Christopher M Dobson
Anne Messer
Bifunctional Anti-Non-Amyloid Component α-Synuclein Nanobodies Are Protective In Situ.
PLoS ONE
title Bifunctional Anti-Non-Amyloid Component α-Synuclein Nanobodies Are Protective In Situ.
title_full Bifunctional Anti-Non-Amyloid Component α-Synuclein Nanobodies Are Protective In Situ.
title_fullStr Bifunctional Anti-Non-Amyloid Component α-Synuclein Nanobodies Are Protective In Situ.
title_full_unstemmed Bifunctional Anti-Non-Amyloid Component α-Synuclein Nanobodies Are Protective In Situ.
title_short Bifunctional Anti-Non-Amyloid Component α-Synuclein Nanobodies Are Protective In Situ.
title_sort bifunctional anti non amyloid component α synuclein nanobodies are protective in situ
url https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0165964&type=printable
work_keys_str_mv AT davidcbutler bifunctionalantinonamyloidcomponentasynucleinnanobodiesareprotectiveinsitu
AT shubhadanjoshi bifunctionalantinonamyloidcomponentasynucleinnanobodiesareprotectiveinsitu
AT erwindegenst bifunctionalantinonamyloidcomponentasynucleinnanobodiesareprotectiveinsitu
AT ankitsbaghel bifunctionalantinonamyloidcomponentasynucleinnanobodiesareprotectiveinsitu
AT christophermdobson bifunctionalantinonamyloidcomponentasynucleinnanobodiesareprotectiveinsitu
AT annemesser bifunctionalantinonamyloidcomponentasynucleinnanobodiesareprotectiveinsitu